Autoinjector Market revenue to cross USD 104.9 Bn by 2025

2022-05-30 14:15:43 UTC | Aerospace & Defense
Autoinjector Market revenue to cross USD 104.9 Bn by 2025

The autoinjectors market, by therapy, is segmented into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, multiple sclerosis, and other therapies (includes cardiovascular diseases, migraine treatment, anemia, and progesterone therapy). Autoinjector Market growth Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages, the increasing number of regulatory approvals, the availability of generic versions of autoinjectors, favorable reimbursements and government support, and technological advancements.  


Global autoinjectors market is projected to reach USD 104.9 billion by 2025 from USD 46.0 billion in 2020, at a CAGR of 17.9% from 2020 to 2025. 


Access Sample Copy of the Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724 


Autoinjectors Market Dynamics 


Driver: Rising incidence of anaphylaxis 


Anaphylaxis is a severe, potentially life-threatening allergic reaction to food, drugs, latex, and Hymenoptera stings. According to a NICE study, anaphylaxis-type reactions occur in ~1 in 1,000 of the general population. During general anesthesia, anaphylaxis occurs in 1 in 10,000–20,000 anesthetics. These patients may be denied general anesthesia in the future unless a safe combination of drugs can be identified. Studies on anaphylaxis epidemiology have reported an annual incidence rate of 1.5–50 per 100,000 person-years. However, most reports are from Western countries such as the US, the UK, and Australia. According to a study published in the European Journal of Allergy and Clinical Immunology in 2019, the incidence of anaphylaxis in children worldwide varied widely, ranging from 1 to 761 per 100,000 person-years for total anaphylaxis and 1 to 77 per 100,000 person-years for food-related anaphylaxis. 


Restraint: Alternative drug delivery modes 

Traditional injectables with vials and syringes are invasive and painful modes of drug delivery, owing to which patients and care providers are increasingly focusing on alternative routes such as oral, topical, and nasal routes. The oral route is the most preferred as it is easy to use, convenient, cost-effective, safe, and acceptable. Moreover, the introduction of needle-free drug delivery devices such as jet injectors also restricts the market growth. For example, Antares Pharma offers jet injectors to deliver growth hormone in the US, Europe, Asia, and Japan. 


Opportunity: Need to limit patient visits and physical contact 

The current COVID-19 pandemic has resulted in the implementation of a fresh set of protocols that aim to reduce patient visits to hospitals and clinics in non-emergency conditions to prevent both the transmission of the virus as much as make sure healthcare institutions are not overwhelmed. In this situation, the preference for home-use autoinjectors has risen among patients suffering from chronic illnesses and allergies. This also protects vulnerable high-risk populations from exposure to the virus during hospital visits. 


 These factors present an opportunity for the growth of the autoinjectors market in the current COVID-19 scenario. 


Challenge: Development of autoinjectors for multiple drug viscosities 

The biggest challenge faced by OEMs is developing single-design autoinjectors for multiple drugs and biologics with varying viscosities. Drugs with different viscosities require springs with different physical characteristics such as composition, length, and thickness to create a spring rate that provides enough power to push higher-viscosity drugs and biologics through the syringe to the needle. Currently, most pharma OEMs lack the knowledge to create autoinjectors capable of delivering multiple drugs and biologics with varying viscosities. However, players are working on overcoming this challenge. For instance, Ypsomed’s Ypsomate 2-step autoinjector has configuration capabilities for different fill volumes and viscosities.   


Asia Pacific is expected to witness fastest growth during the forecast period of 2020–2025. 

Geographically, the autoinjectors market is segmented into North America, Europe, the Asia Pacific, Latin America, and Middle East & Africa. Growth in the Asia Pacific market is driven majorly by the large diabetes population and increasing healthcare expenditure in the regional countries have drawn a number of major autoinjector device manufacturers to this region. These companies are increasing their presence in the Asia Pacific market through several approaches, such as establishing sales offices and partnering with local pharmaceutical companies 


The prominent players in this market are AbbVie Inc. (US), Mylan (US), Eli Lilly and Company (US), Ypsomed (Switzerland), Amgen (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), Johnson & Johnson (US), Teva Pharmaceutical (Israel), Antares Pharma (US), Merck KGaA (Germany). 


Recent Developments 

  • In August 2020, Antares Pharma (US) signed an agreement with Lunatus Global Medical Supplies (Dubai). In this agreement, Antares will supply packaged products to Lunatus and Lunatus will submit and obtain regulatory approval for XYOSTED in the UAE and Saudi Arabia as well as promote, market, and distribute XYOSTED in these two countries. 

  • In March 2020, SHL Medical (Switzerland) acquired Weibel CDS (Switzerland). This acquisition aimed at strengthening SHL Medical’s ability to provide more advanced drug delivery systems based on human-centered designs and functionality. 

  • In January 2020, Eli Lilly invested USD 470 million and created over 460 new jobs in Durham, NC. This expansion brought a new state-of-the-art pharmaceutical manufacturing facility to North Carolina’s research triangle park. 

  • In November 2019, Becton, Dickinson and Company (US) launched a disposable autoinjector namely BD Intevia 1ml Disposable Autoinjector. This activity will strengthen company’s autoinjector’s portfolio. 

Top